N-2-methoxyethylfurfurylamine | 831203-36-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-2-methoxyethylfurfurylamine
• 英文别名: furan-2-ylmethyl-(2-methoxy-ethyl)-amine；N-(2-furylmethyl)-N-(2-methoxyethyl)amine；N-(furan-2-ylmethyl)-2-methoxyethanamine
• CAS: 831203-36-2
• 化学式: C₈H₁₃NO₂
• mdl: MFCD06740596
• 分子量: 155.197
• InChiKey: SORZPLSUZRRMRL-UHFFFAOYSA-N

物化性质

• 沸点：
  199.2±20.0 °C(Predicted)
• 密度：
  1.012±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  34.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2932190090

反应信息

• 作为反应物：
  描述：

  N-2-methoxyethylfurfurylamine 在 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 3.0h， 生成 2-(2-甲氧基-乙基)-3-氧代-2,3-二氢-1H-异吲哚-4-羧酸
  参考文献：
  名称：

  Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy

  摘要：

  The nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) has a well-established role in the signaling and repair of DNA and is a prominent target in oncology, as testified by the number of candidates in clinical testing that unselectively target both PARP-1 and its closest isoform PARP-2. The goal of our program was to find a PARP-1 selective inhibitor that would potentially mitigate toxicities arising from cross-inhibition of PARP-2. Thus, an HTS campaign on the proprietary Nerviano Medical Sciences (NMS) chemical collection, followed by SAR optimization, allowed us to discover 2-[1-4,4-difluorocyclohexyl)piperidin-4-yl] -6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118, 20by). NMS-P118 proved to be a potent, orally available, and highly selective PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles and high efficacy in vivo both as a single agent and in combination with Temozolomide in MDA-MB-436 and Capan-1 xenograft models, respectively. Cocrystal structures of 20by with both PARP-1 and PARP-2 catalytic domain proteins allowed rationalization of the observed selectivity.

  DOI：

  10.1021/acs.jmedchem.5b00680
• 作为产物：
  描述：

  furfurylidene-(2-methoxy-ethyl)-amine 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 生成 N-2-methoxyethylfurfurylamine
  参考文献：
  名称：

  Preparative Synthesis of 7-Carboxy-2-R-isoindol-1-ones

  摘要：

  DOI：

  10.1023/b:cohc.0000023763.75894.63

文献信息

• The 3F Library: Fluorinated Fsp ³ ‐Rich Fragments for Expeditious ¹⁹ F NMR Based Screening
  作者：Nikolaj S. Troelsen、Elena Shanina、Diego Gonzalez‐Romero、Daniela Danková、Ida S. A. Jensen、Katarzyna J. Śniady、Faranak Nami、Hengxi Zhang、Christoph Rademacher、Ana Cuenda、Charlotte H. Gotfredsen、Mads H. Clausen

  DOI：10.1002/anie.201913125

  日期：2020.2.3

  still suffers from laborious screening workflows and a limited diversity in the fragments applied. Presented here is the design, synthesis, and biological evaluation of the first fragment library specifically tailored to tackle both these challenges. The 3F library of 115 fluorinated, Fsp3 -rich fragments is shape diverse and natural-product-like with desirable physicochemical properties. The library

  基于片段的药物发现（FBDD）是学术界和制药行业中发现早期潜在候选药物的一种流行方法。尽管其用途广泛，但该方法仍存在费时费力的筛选工作流程，并且所用片段的多样性有限。这里介绍的是第一个片段库的设计，合成和生物学评估，这些片段库专门为应对这些挑战而设计。115个富含Fsp3的氟化片段的3F文库形状多样，呈天然产物状，具有理想的理化性质。该文库非常适合在19 F NMR和随后的1 H NMR方法的两阶段工作流程中通过NMR光谱进行快速有效的筛选。在3F库中的片段支架中，针对四种不同蛋白质靶标的命中分布广泛，使用二级检测的确证率达到67％。该集合是为19 F NMR筛选量身定制的第一个合成片段文库，结果表明该方法应在FBDD社区中得到广泛应用。
• [EN] TRPM8 ANTAGONISTS<br/>[FR] ANTAGONISTES DE TRPM8
  申请人：DOMPE SPA

  公开号：WO2013092711A1

  公开（公告）日：2013-06-27

  The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exhacerbated respiratory disorders and urological disorders.

  该发明涉及作为Transient Receptor Potential阳离子通道亚家族M成员8 (TRPM8)的选择性拮抗剂的化合物，其化学式为(I)。所述化合物在治疗与TRPM8活性相关的疾病方面具有用途，如疼痛、炎症、缺血、神经退行性疾病、中风、精神障碍、瘙痒、肠易激综合征、冷诱导和/或加重的呼吸道疾病以及泌尿系统疾病。
• 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS
  申请人：Papeo Gianluca Mariano Enrico

  公开号：US20120245142A1

  公开（公告）日：2012-09-27

  There are provided substituted 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide derivatives (I) which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating, diseases utilizing pharmaceutical compositions comprising these compounds.

  本发明提供了替代的3-氧代-2,3-二氢-1H-异吲哚-4-羧酰胺衍生物（I），其能够选择性地抑制PARP-1相对于PARP-2的活性。因此，本发明的化合物可用于治疗癌症、心血管疾病、中枢神经系统损伤和不同形式的炎症等疾病。本发明还提供了制备这些化合物的方法、包含这些化合物的制药组合物以及利用包含这些化合物的制药组合物治疗疾病的方法。
• [EN] 3-OXO-2, 3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS<br/>[FR] 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES EN TANT QU'INHIBITEURS DE PARP
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2011006794A9

  公开（公告）日：2011-05-05
• 3-OXO-2, 3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS
  申请人：Nerviano Medical Sciences S.r.l.

  公开号：EP2454236A1

  公开（公告）日：2012-05-23